Showing 5961-5970 of 7740 results for "".
- Almirall Launches New Series Highlighting the Impact of Psoriasis on Wellbeinghttps://practicaldermatology.com/news/almirall-launches-new-series-highlighting-the-impact-of-psoriasis-on-wellbeing/2461795/Almirall has launched Nina, a three-episode series about the life of a fashion designer with psoriasis to illustrate a journey from darkness to light. Nina narrates the story of an introverted designer portrayed by Spanish actress Alba Ribas (Cable Girls, Netflix). One da
- Study: Minimal Systemic Absorption of Isotretinoin Seen in Congenital Ichthyosishttps://practicaldermatology.com/news/study-minimal-systemic-absorption-of-isotretinoin-seen-in-congenital-ichthyosis/2461793/Interim pharmacokinetic (PK) analyses from the Phase 3 ASCEND study suggest minimal systemic absorption of isotretinoin or its major metabolites in patients with moderate to severe forms of congenital ichthyosis (CI) who were treated with TMB-001 0.05% ointment, Timber Pharmaceuticals, Inc. repor
- Health Canada Greenlights Sun Pharma’s Winlevi for Acnehttps://practicaldermatology.com/news/health-canada-greenlights-sun-pharmas-winlevi-for-acne/2461792/Health Canada has given its nod to Sun Pharma’s Winlevi (clascoterone cream 1%). Winlevi an androgen receptor inhibitor indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. It will be available in Canada this Fall. "
- Zydus Lifesciences Scores FDA Nod for Generic Acne Drughttps://practicaldermatology.com/news/zydus-lifesciences-scores-fda-nod-for-generic-acne-drug/2461791/The U.S. Food and Drug Administration (FDA) has given its nod to Zydus Lifesciences’ generic antibiotic minocycline hydrochloride extended-release tablets for the treatment of moderate to severe acne in 55 mg, 65 mg, and 115 mg doses, the Company reports. Minocycline hyd
- Sirnaomics Gets FDA Go Ahead to Move STP705 Into Late-Stage Clinical Development for isSCChttps://practicaldermatology.com/news/sirnaomics-gets-fda-go-ahead-to-move-stp705-into-late-stage-clinical-development-for-isscc/2461788/Sirnaomics Ltd.’s STP705 for the treatment of Squamous Cell Carcinoma in situ (isSCC) is moving into late-stage clinical development after encouraging Phase IIa and Phase IIb clinical results. These results were shared with the U.S. Food and Drug Administration (FDA) in an En
- FDA Nod for Avita Medical’s RECELL for Skin Repigmentation in Vitiligo Patientshttps://practicaldermatology.com/news/fda-nod-for-avita-medicals-recell-for-skin-repigmentation-in-vitiligo-patients/2461787/The U.S. Food and Drug Administration (FDA) has approved AVITA Medical, Inc.’s application for premarket approval (PMA) of its RECELL System for the treatment of vitiligo. RECELL for repigmentation of stable depigmented vitiligo lesions is the first FDA-approved therapeutic d
- Merz Aesthetics News: Xeomin Scores in Phase 3 Studies of Upper Facial Lineshttps://practicaldermatology.com/news/merz-aesthetics-news-xeomin-performs-well-in-phase-3-studies-of-upper-facial-lines/2461781/Two pivotal phase 3 clinical studies demonstrated the efficacy and safety of Xeomin (incobotulinumtoxinA) in the simultaneous treatment of horizontal forehead lines, glabellar frown lines, and lateral canthal lines, according to Merz Aesthetics. Merz Aesthetics will submit these data as
- And the Winners Are…Botox Cosmetic Announces the Winners of the IFundWomen Grant Programhttps://practicaldermatology.com/news/and-the-winners-arebotox-cosmetic-announces-the-winners-of-the-ifundwomen-grant-program/2461779/Twenty female entrepreneurs will receive funding and mentorship through Allergan’s BOTOX Cosmetic and IFundWomen grant program. "There were so many remarkable applications that featured thoughtful business solutions," says Carrie Strom, President, Global Aller
- Dermwire Chats with HS Docuseries Host Jasmine Ivanna Espyhttps://practicaldermatology.com/news/directors-cut-dermwire-chats-with-hs-docuseries-director-jasmine-ivanna-espy/2461776/Thanks to a burgeoning pipeline of potential new treatments and new education and awareness efforts, hidradenitis suppurativa (HS) is finally getting the attention that it deserves. Novartis recently premiered a new docuseries on life with HS at the 2023 Tribeca Film Fest
- Study Uncovers How B Cells React to Melanomahttps://practicaldermatology.com/news/study-uncovers-how-b-cells-react-to-melanoma/2461773/Antibody-producing B cells may be defective in responding to melanoma, a new study suggests. The study is published in Nature Communications. Researchers used advanced technologies to delve into the antibody immune response in blood and tissues of patients with m